title: Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests.
abstract: We collected peripheral blood stem cells (PBSC) in 19 early chronic phase CML patients following each of two consecutive cycles of intensive chemotherapy (CT) to evaluate whether an additional cycle of CT would increase Philadelphia (Ph)-negativity of the PBSC harvest. Autologous SCT (autoSCT) was performed if a major cytogenetic response (MCR) of the PBSC harvest was obtained. CT consisted of cytarabine 200 mg/ m2/day (days 1-7)/idarubicin 12 mg/m2/day (days 1-2) (cycle one) and cytarabine 2000 mg/m2/day (days 1-6)/amsacrine 120 mg/m2/day (days 1-3) (cycle two). One patient died of fungal pneumonia after the first cycle. Stem cells were harvested in 18 patients after cycle one and in 16 patients after cycle two. After the first cycle, all patients showed a cytogenetic response of their graft (MCR in eight patients: three complete, five partial), after cycle two, seven patients obtained an MCR (one complete, six partial). Seven patients became eligible for autoSCT. All patients proceeded with IFNalpha maintenance. Currently, 16 patients are alive. At the latest cytogenetic examination of bone marrow, four patients showed an MCR and four a minor response. In conclusion, although a second cycle of CT may contribute to elimination of leukemia residing in the patient, it appeared to be ineffective in improving the Ph-negativity of the PBSC graft.
authors.affiliation: Department of Haematology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.
authors.forename: J J
authors.initials: JJ
authors.lastname: Janssen
authors.forename: R S
authors.initials: RS
authors.lastname: van Rijn
authors.forename: B
authors.initials: B
authors.lastname: van der Holt
authors.forename: G J
authors.initials: GJ
authors.lastname: Schuurhuis
authors.forename: E
authors.initials: E
authors.lastname: Vellenga
authors.forename: G E
authors.initials: GE
authors.lastname: Verhoef
authors.forename: G J
authors.initials: GJ
authors.lastname: Ossenkoppele
authors.forename: E
authors.initials: E
authors.lastname: van den Berg
authors.forename: A
authors.initials: A
authors.lastname: Hagemeijer
authors.forename: R
authors.initials: R
authors.lastname: Släter
authors.forename: A W
authors.initials: AW
authors.lastname: Nieuwint
authors.forename: J J
authors.initials: JJ
authors.lastname: Cornelissen
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D014182:Transplantation, Autologous
chemical_list: D016898:Interferon-alpha; D003561:Cytarabine; D015255:Idarubicin